Search Bar & Filters
Found 11 Actively Recruiting clinical trials
Actively Recruiting
This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of divarasib combined with pembrolizumab compared with pembrolizumab plus pemetrexed and carboplatin or cisplatin for adults with KRAS G12C-mutated, advanced or metastatic non-squamous non-small cell lung cancer NSCLC who have not received prior treatment. This phase 3 randomized study aims to find the best first-line therapy option for this specific lung cancer type. Participants are randomly assigned to one of two groups one group receives divarasib orally once daily and pembrolizumab through intravenous infusion every three weeks, while the other group receives pembrolizumab, pemetrexed, and carboplatin or cisplatin all by intravenous infusion every three weeks. The study treatments are given as first-line therapy, and participants are monitored for up to approximately five years. During the study, participants undergo regular assessments including scans to measure tumor response, evaluations of lung cancer symptoms like cough and breathlessness, quality of life questionnaires, and monitoring for side effects. Researchers track progression-free survival and overall survival for up to about five years. Safety and symptom severity are closely followed throughout the study, providing comprehensive data on treatment impact and participant well-being.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of TAR-210 compared to intravesical chemotherapy in treating high-risk non-muscle-invasive bladder cancer HR-NMIBC. This Phase 3 study focuses on disease-free survival, which is the length of time participants live without signs or symptoms of cancer returning or worsening. The study targets patients with specific FGFR genetic alterations who have previously received BCG treatment but remain at high risk for cancer recurrence. Participants are randomly assigned to one of two groups Group A will have the investigational drug TAR-210 placed inside the bladder on Day 1 and continue treatment for about two years. Group B will receive intravesical chemotherapy with either mitomycin C or gemcitabine weekly for 4 to 6 doses, followed by monthly maintenance for up to one year, with an optional second year of maintenance depending on the investigators decision. All treatments are delivered directly into the bladder. Throughout the study, participants will have regular assessments including monitoring for cancer recurrence, progression, and overall survival for up to five years. Researchers will collect safety data such as adverse events and changes in laboratory tests and vital signs. Quality of life will be measured using specific questionnaires at multiple time points. The study involves ongoing visits and evaluations to closely observe treatment effects and participant well-being over the long term.
Actively Recruiting
Researchers are evaluating the effects of muvalaplin in reducing the risk of major cardiovascular events in adults with elevated lipoproteina levels who either have cardiovascular disease or are at risk for a heart attack or stroke. This Phase 3, randomized, double-blind, placebo-controlled study focuses on adults with high lipoproteina and a history or risk of atherosclerotic cardiovascular events. The study aims to better understand if muvalaplin can lower the occurrence of serious heart-related problems. Participants will be randomly assigned to receive either muvalaplin or a placebo, both taken orally. The study compares these two groups over about 5.25 years to assess the impact of muvalaplin on major adverse cardiac events. The research includes ongoing monitoring of lipoproteina levels and other cardiovascular outcomes throughout this period. During the study, participants will undergo regular assessments including measuring changes in lipoproteina, tracking the time to occurrence of major cardiovascular events, and monitoring overall health outcomes. Researchers will collect data on healthcare resource usage and drug levels in the body. The long-term follow-up allows for thorough evaluation of muvalaplins effects on heart health and safety over more than five years.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of a new oral cladribine formulation in adults with Generalized Myasthenia Gravis gMG. This Phase 3 clinical trial compares two doses of cladribine with a placebo and also studies the long-term safety, sustained effects, and need for retreatment of cladribine in people with gMG. Additionally, the study will examine how the body processes cladribine through a pharmacokinetic sub-study. Participants are randomly assigned to one of three groups placebo, low dose cladribine, or high dose cladribine. Each group receives two separate treatment courses orally, starting on Day 1 and again at Week 5 during the double-blind placebo-controlled period. After this, participants enter a blinded extension where those initially on placebo switch to cladribine doses, and those initially on cladribine receive placebo courses. If needed, participants may enter a retreatment period to receive additional cladribine or placebo doses based on clinical judgment. During the study, participants undergo regular assessments including changes in muscle weakness and daily living activities using specific scales like the MG-ADL. Safety is monitored through tracking adverse events, lab tests, vital signs, and heart monitoring. The study also includes in-depth interviews with a subset of participants to understand their treatment and study experience. The total study duration extends up to 144 weeks, allowing long-term follow-up and evaluation.
Actively Recruiting
Researchers are evaluating the effect and safety of orforglipron taken once daily in adults with Fontaine Stage II peripheral arterial disease PAD, a condition that causes symptoms like leg pain due to poor blood flow. The study is a phase 3 randomized, double-blind, placebo-controlled trial aiming to better understand how this treatment impacts walking ability and quality of life in this population. Participation is expected to last about 58 weeks. Participants are randomly assigned to receive either orforglipron or a placebo, both taken orally once daily. The study compares these two groups to assess changes in walking distances and other health measures over the course of the trial. This design helps evaluate the medications effect compared to no active treatment. During the study, participants undergo assessments including measuring maximum and pain-free walking distances, vascular quality of life via questionnaire, the six-minute walk test, blood markers like high-sensitivity C-reactive protein, and systolic blood pressure. These measurements occur at the start and after 52 weeks of treatment. Safety and effectiveness are monitored throughout, with overall participation lasting nearly a year.
Actively Recruiting
Researchers are evaluating the safety and clinical effects of Awiqli in people with diabetes mellitus in Japan during routine medical care. This observational study aims to collect real-world data on the use of Awiqli over a one-year period. The study focuses on participants with any type of diabetes who are prescribed Awiqli independently of the study. Participants will receive commercially available Awiqli as directed by their treating doctors according to standard clinical practice. There is no experimental treatment assignment as this is a non-interventional study. The study observes the use of Awiqli over 52 weeks without altering usual care. During the study, participants will be monitored for adverse reactions and events, serious adverse events, and changes in diabetes-related clinical parameters including HbA1c, fasting plasma glucose, and diabetes therapy-related quality of life. Data will be collected from baseline through week 52. The total participation time lasts about one year.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the Double-effect kissing balloon technique W-KBT using Perfusion balloon PB and Drug coated balloon DCB in patients with left main coronary artery disease LMD who have left circumflex artery LCx ostium stenosis. This prospective, observational, multi-center study focuses on patients with stable angina, non-ST-elevation myocardial infarction, or unstable angina who require percutaneous coronary intervention PCI. Patients who meet the selection criteria will receive PCI with W-KBT following crossover stenting for LMT-LAD direction, proximal optimization technique POT, and conventional kissing balloon technique C-KBT as part of usual care. Approximately 280 participants aged 18 and older will be enrolled across 17 sites in Japan. The study will monitor patients through hospital discharge and for 12 months afterward during routine clinical practice. Participants will be followed to assess procedure success during PCI and major adverse cardiovascular events MACE within 12 months. Additional measures include time to ST-change from DCB inflation, total DCB inflation time, changes in blood pressure and heart rate, use of vasopressors or mechanical support after W-KBT, and incidence of ischemia-driven revascularization at the LCx ostium. Data will be collected to evaluate the efficacy and safety of this treatment approach over the year following the procedure.
Actively Recruiting
Researchers are evaluating the overall survival of patients with stage I epithelial ovarian cancer after they have undergone comprehensive staging surgery. This phase III trial compares the outcomes of adjuvant chemotherapy versus observation alone. The study aims to determine whether adding chemotherapy after surgery improves survival in this patient group. Participants will be randomly assigned to one of two groups. One group receives adjuvant chemotherapy, which includes either a combination of paclitaxel and carboplatin or docetaxel and carboplatin, given every three weeks for three to six cycles. Switching between paclitaxel and docetaxel is allowed if adverse events occur. The other group undergoes observation without chemotherapy. During the study, participants will be monitored for overall survival up to 60 months from randomization. Researchers will also assess relapse-free survival within the same timeframe. Evaluations include follow-ups to track disease progression, side effects, and general health. The study ensures participants receive appropriate care and measures outcomes to better understand treatment benefits and risks.
Actively Recruiting
Researchers are evaluating the efficacy and safety of Datopotamab Deruxtecan Dato-DXd combined with Rilvegostomig, or Rilvegostomig alone, compared with Pembrolizumab alone as first-line treatments for people with locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC. Participants must have high PD-L1 expression tumor cells 50% and no actionable genomic mutations. This is a Phase III, randomized, open-label global study focusing on these treatments for this specific lung cancer type. Participants will be assigned to one of three groups one receiving Dato-DXd plus Rilvegostomig, another receiving Rilvegostomig alone, and a third receiving Pembrolizumab alone. All treatments are given by intravenous infusion every three weeks on Day 1 of each 21-day cycle. The study will monitor participants over several years to compare these therapies as first-line options. During the study, participants will undergo regular assessments including imaging and tumor sampling to measure progression-free survival and overall survival, focusing on those with TROP2 biomarker positivity. Other evaluations include response rates, duration of response, lung cancer symptoms, quality of life, physical functioning, pharmacokinetics, and immunogenicity over approximately 4 to 6 years. Safety monitoring and long-term follow-up are part of the participant involvement.
1-10 of 11
1